Ascendis Pharma A/S
ASND
177 hedge funds and large institutions have $6.83B invested in Ascendis Pharma A/S in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 83 increasing their positions, 53 reducing their positions, and 20 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 53
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
2% more funds holding
Funds holding: 173 → 177 (+4)
1% less call options, than puts
Call options by funds: $18.1M | Put options by funds: $18.4M
4.32% less ownership
Funds ownership: 102.81% → 98.48% (-4.3%)
25% less capital invested
Capital invested by funds: $9.06B → $6.83B (-$2.23B)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$83.1M |
| 2 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
+$82.4M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$42.5M |
| 4 |
SCM
Spyglass Capital Management
San Francisco,
California
|
+$41M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$38.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$300M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$235M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$89.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$31.2M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$20.3M |
ASND Hedge Fund Activity: Q1 2021 in Review
177 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2021, worth a combined $6.83B — down 25% from $9.06B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ASND positions and 20 closed out — a net gain of 5 holders — while 83 added to existing stakes and 53 trimmed.
The largest buyer was RA Capital Management, adding an estimated $83.1M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $300M sold.
- 177 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2021, up from 173 in Q4 2020.
- Funds reported $6.83B of Ascendis Pharma A/S stock for Q1 2021, down 25% quarter-over-quarter.
- 25 funds opened new Ascendis Pharma A/S positions in Q1 2021 and 20 closed out, a net change of +5 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2021 was RA Capital Management, an estimated $83.1M added.
- The largest Ascendis Pharma A/S seller in Q1 2021 was Avoro Capital Advisors, an estimated $300M sold.
Based on aggregated 13F filings for Q1 2021.